Navigation Links
Outwitting immunity to treat disease: Start-up raises 37 millions dollars
Date:5/5/2014

What do multiple sclerosis, type I diabetes and food allergies have in common? All these conditions are caused by an abnormal immune response; white blood cells that attack their own body cells or overreact to external elements. In EPFL's Innovation Park, the start-up company Anokion is developing an extremely promising technology to treat autoimmune conditions and other maladies. The first clinical trials are planned for 2017.

And the range of applications isn't just limited to autoimmune disease. The body also develops immune reactions to many protein drugs used to treat hemophilia and cancer, for example, and Anokion's approach may be able to prevent these reactions as well. Now, a group of venture capitalists specializing in pharmaceuticals (Novartis Venture Fund, Novo Ventures and Versant Ventures) has recognized the potential and injected 37 million dollars (33 million Swiss francs) into the young company.

How to trick the immune system

Anokion's technology takes advantage of a behavior exhibited by white blood cells that is still not very well understood. These cells, the advance guard of the immune system, tend to calm down in the presence of cells that are dying normally at the end of their life cycle. Their cousins, the red blood cells, do just that in healthy individuals, turning over en masse on the order of 200 million per day.

The researchers developed a technique to attach the protein responsible for triggering the immune response onto these red blood cells. A bit like Pavlov's dogs, who learned to associate the sound of a bell with the appearance of food, the white blood cells associate the "foreign" protein with the millions of calming messages released every day by the red blood cells as they expire. The undesirable immune response disappears. In 2012, the EPFL laboratory led by Jeffrey Hubbell used this technique to prevent disease in mice that were developing type I diabetes. The research was published in PNAS and received an enormous amount of attention.

"The technology delivers proteins, be they autoimmune antigens or protein drugs, in a manner that re-trains the immune system to accept them as the body's own," explains Hubbell "We are delighted that leading biotech venture funds have recognized the value of our approach, providing the necessary financial means to move forward."

Anokion's mission is to commercialize this discovery so that it can move out of the lab and into use as a treatment for disease. For now, the researchers are concentrating on a specific kind of white blood cell, T lymphocytes, that are implicated in many autoimmune and allergic diseases, including multiple sclerosis and type I diabetes.

The technology has a far wider potential, however. Protein drugs are used to treat diseases such as cancer and a number of genetic diseases such as hemophilia. Despite their effectiveness in treating these diseases, the body frequently recognizes these proteins as foreign and mounts an immune response against them, sometimes even after one or a few doses. After this, the body neutralizes the protein drugs that have been developed to heal it.

Using Anokion's technique, the drug could be administered over a much longer period by teaching the immune system to leave it alone. Multiple therapeutic molecules that trigger immune reactions have been withdrawn after clinical trials due to these immunogenicity challenges. The researchers think that many of these could be rehabilitated if the immune response of the T-cells during treatment could be controlled.

Anokion is planning clinical trials for 2017. They will initially test their technology in conjunction with a drug known to trigger strong immune reactions before moving on to autoimmune diseases.


'/>"/>

Contact: Lionel Pousaz
lionel.pousaz@epfl.ch
41-795-597-161
Ecole Polytechnique Fdrale de Lausanne
Source:Eurekalert

Related medicine news :

1. Researchers generate immunity against tumor vessel protein
2. Testosterone-regulated genes may affect vaccine-induced immunity
3. Combat the Flu with Immunity Products from Kirkman®
4. Maternal smoking may impair infant immunity, causing a broad range of infections
5. Wiley launches new open access journal: Immunity, Inflammation and Disease
6. Anxiety about relationships may lower immunity, increase vulnerability to illness
7. Regulatory immune cell diversity tempers autoimmunity in rheumatoid arthritis
8. From herd immunity and complacency to group panic: How vaccine scares unfold
9. Study unveils new approach to treating brittle bone disease
10. Study points to potential revision of treatment guidelines for bleeding ulcers
11. Vibrating capsule shows promising results in treating chronic constipation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... management software and services, is proud to announce it has joined the National ... association representing the interests of chronically ill, disabled, and dying Americans of all ...
(Date:3/28/2017)... ... March 28, 2017 , ... Via Oncology, the ... launch of a free, public-facing tool for analyzing the costs of various drug ... provide comparative information to patients, providers, insurers and pharmaceutical companies about the estimated ...
(Date:3/28/2017)... ... March 28, 2017 , ... Z-Medica, LLC, a leading ... Medical Center (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) to equip up ... association with efforts by the American College of Surgeons, U.S. Department of Defense, ...
(Date:3/28/2017)... ... March 28, 2017 , ... Usually, the impending arrival of warmer weather ... those self-conscious about a double chin, this means more anxiety than elation. The cosmetic ... “For most people, a double chin is undesirable,” Dr. Goldman said, “but it seems ...
(Date:3/28/2017)... ... 28, 2017 , ... Calibration, qualification, and the appropriate level ... maintaining GMP and USP compliance. In a new webinar from METTLER TOLEDO entitled ... these requirements are explained. The challenge is to determine how to put ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Neurim Pharmaceuticals ("Neurim") and Exeltis announced today ... for Neurim,s new Rx PedPRM in Spain . ... Neurim,s paediatric prolonged-release ... children with Autism Spectrum Disorders (ASD) and neurogenetic diseases. It is ... The collaboration with Exeltis will help increase the accessibility of ...
(Date:3/29/2017)... FinancialBuzz.com News Commentary  ... The U.S. could see significant economic benefits from the expanding ... Frontier Data, the legal cannabis market is projected to create 283,422 ... the United States , as well as the economic ... that drives growth in this sector. Medical cannabis is now legal ...
(Date:3/28/2017)... LONDON , March 28, 2017 The ... at a CAGR of 13.45% from 2016 to 2023 ... Description Cancer is a chronic disease ... emerging in the cancer diagnostics market. This report is ... tumor test. The market growth is propelled due to ...
Breaking Medicine Technology: